Therapy News and Research

RSS

European collaboration to design a biomimetic bioartificial liver

Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management.

2 Jul 2012

Blocking AXL protein may prevent resistance to lung cancer drug

People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.

2 Jul 2012

Early brain changes predict chances of developing chronic pain

When people have similar injuries, why do some end up with chronic pain while others recover and are pain free? The first longitudinal brain imaging study to track participants with a new back injury has found the chronic pain is all in their heads -- quite literally.

2 Jul 2012

3D printed templates of filament networks can improve function of engineered living tissues

Researchers are hopeful that new advances in tissue engineering and regenerative medicine could one day make a replacement liver from a patient's own cells, or animal muscle tissue that could be cut into steaks without ever being inside a cow.

2 Jul 2012

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

2 Jul 2012

Textile cooling pads to prevent neurological damage after successful resuscitation

Textile cooling pads are to be used in future to prevent neurological damage after successful resuscitation. The system developed by scientists from the Hohenstein Institute in Bönnigheim requires no electric power, making it ideal especially for first aid in case of cardiac arrest.

30 Jun 2012

Study details canonical Wnt signaling pathway

Many lung cancers are driven by mutations in the epidermal growth-factor receptor (EGFR), and so it makes sense that many successful modern treatments block EGFR activity. Unfortunately, cancers inevitably evolve around EGFR inhibition, and patients with lung cancers eventually relapse.

30 Jun 2012

Longer looks: Native American rehab facility helps families in Ore.; Growing popularity of home births; Sexuality in the nursing home

Pearl Scott lifts the baby from the crib and balances the child on her hip, just as someone did with her when she was a baby 20 years ago. Her mom went through addiction treatment here in the Native American Rehabilitation Association of the Northwest's residential center. Now Scott works for NARA, operated by and for Native Americans. She helps care for the 10 children, all 5 years old and younger, of parents in treatment.

30 Jun 2012

$Epilepsy patients unaware of fracture risk$

Epilepsy patients unaware of fracture risk

Few patients with epilepsy are aware that taking anti-epileptic drugs puts them at increased risk for falls and fractures, report researchers.

29 Jun 2012

Liraglutide efficacy in Japanese patients “easy” to predict

Liraglutide therapy is an effective alternative to basal-supported oral therapy for some Japanese patients with diabetes, while it is completely ineffective for others, report researchers.

29 Jun 2012

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

29 Jun 2012

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

HIV therapy has traditionally been associated with antiretrovirals, which considerably reduce the amount of virus present in the blood to nearly undetectable levels.

29 Jun 2012

Lexicon announces results from two initial trials of LX4211 for type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics.

29 Jun 2012

ACR updates 39 appropriateness criteria topics and adds five new criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

29 Jun 2012

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could - paradoxically - shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.

29 Jun 2012

Once-daily pill for HIV is a safe and effective alternative to traditional antiretroviral regimens

A new once-daily pill combining three antiretrovirals and a booster molecule is a safe and effective alternative to two widely used drug regimens for newly diagnosed HIV-positive adults who have had no previous treatment. The findings of two large international randomised trials published in this week’s Lancet also indicate that the new “Quad” pill is faster acting, doesn’t have the neuropsychiatric side effects associated with other combinations, and could improve compliance with treatment.

29 Jun 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012

Researchers use DNA molecules to stimulate repair of nerve coatings that mimic MS

Mayo Clinic researchers have successfully used smaller, folded DNA molecules to stimulate regeneration and repair of nerve coatings in mice that mimic multiple sclerosis (MS). They say the finding, published today in the journal PLoS ONE, suggests new possible therapies for MS patients.

29 Jun 2012

AASLD, EASL to hold special conference on therapy of HCV

The European Association for the Study of the Liver (EASL), together with the American Association for the Study of Liver Diseases (AASLD), will be holding an exciting "Special Conference" dedicated to the timely topic of: Therapy of Hepatitis C: Clinical Application and Drug Development.

29 Jun 2012

Benefits of complementary and alternative medicine for back pain

Got a pain in the neck or back? Relief could be just an adjustment away. In a recent study, "Perceived Benefit of Complementary and Alternative Medicine (CAM) for Back Pain" (Journal of the American Board of Family Medicine, May - June 2010, Vol. 23 No.3), the majority of respondents receiving CAM for back pain reported significant benefits from the various treatments.

29 Jun 2012